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ABSTRACT: The several biological barriers that nanoparticles might encounter
when administered to a patient constitute the major bottleneck of nanoparticle-
mediated tumor drug delivery, preventing their successful translation into the
clinic and reducing their therapeutic profile. In this work, mesoporous silica
nanoparticles have been employed as a platform to engineer a versatile
nanomedicine able to address such barriers, achieving (a) excessive premature
drug release control, (b) accumulation in tumor tissues, (c) selective
internalization in tumoral cells, and (d) endosomal escape. The nanoparticles
have been decorated with a self-immolative redox-responsive linker to prevent
excessive premature release, to which a versatile and polyvalent peptide that is
able to recognize tumoral cells and induce the delivery of the nanoparticles to the
cytoplasm via endosomal escape has been grafted. The excellent biological
performance of the carrier has been demonstrated using 2D and 3D in vitro cell
cultures and a tumor-bearing chicken embryo model, demonstrating in all cases
high biocompatibility and cytotoxic effect, efficient endosomal escape and tumor penetration, and accumulation in tumors grown on
the chorioallantoic membrane of chicken embryos.
KEYWORDS: mesoporous silica nanoparticles, stimuli-responsive, drug delivery, redox-responsive, self-immolative, targeting,
endosomal escape, chicken embryo model
■ INTRODUCTION
According to World Health Organization reports, cancer is
currently a leading cause of death worldwide, with almost 10
million cancer deaths in 2018.1 The number of new cases is
expected to reach 25 million over the next two decades.2
Among current cancer treatments, chemotherapy lacks tumor
tissue selectivity, which leads to nonspecific drug distribution
and subsequent toxicity to the patient. In this sense,
nanoparticles have emerged as a compelling weapon to
encapsulate cytotoxics and deliver them to cancerous cells,
reducing those potential side effects.3−5 Among all the
available nanocarriers, mesoporous silica nanoparticles
(MSNs) have drawn attention owing to their exquisite
properties, including a network of hollow cavities with the
subsequent large surface areas (ca. 1000 m2/g) and pore
volumes (ca. 1 cm3/g), tunable pore size and morphologies,
facile surface modification, and biocompatibility.6−10 Their
open porous structure suggests that the cargo molecules could
easily diffuse out of the pores before reaching their target cells.
This premature release can be diminished using stimuli-
responsive gatekeepers. Those are structures that are able to
open and close the pore gates in response to certain stimuli
(internal or external).11−14 That responsive behavior can be
accomplished using different types of gatekeepers, such as
those based on self-immolative chemistry.15−17 These
structures degrade in a domino-like fashion when a triggering
moiety is removed from the backbone upon application of a
very specific stimulus.18,19 In this sense, glutathione is
overexpressed within the cytoplasm of cancer cells and can
be employed to initiate the self-immolation of different redox-
responsive structures.20−25
Although research on nanoparticles for drug delivery in
cancer has been thoroughly investigated in the laboratory, few
of them have reached the bed side. In fact, and despite all
benefits that nanoparticles might offer, they have to face several
biological barriers that might prevent their effective use for
tumor drug delivery. Examples of these barriers include (1)
lack of tumor tissue selectivity, (2) lack of selective cancer cell
recognition, or (3) endolysosomal sequestration, among
others.26,27
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In this sense, it is well-known that the presence of
fenestrations in the tumor blood vessels and the poor
lymphatic drainage in the tissue promotes the passive
accumulation of nanomedicines in the tumors. In consequence,
the so-called enhanced permeability and retention (EPR) effect
would provide an effective approximation to tackle the lack of
tumor tissue selectivity.28 In addition, the overexpression of
specific membrane receptors of tumoral cells enables their
selective recognition by modifying the nanoparticles surface
with molecules showing high affinity for those receptors. In
this manner, nanoparticles would be selectively internalized,
thereby addressing the lack of selectivity toward tumoral
cells.29,30 Following internalization of nanocarriers, they might
be sequestered within the acidic endolysosomes, which might
lead to cargo degradation and reduced therapeutic effect.26 In
this sense, these vesicles might be disrupted by modifying the
particles with species with buffering capacity. These moieties
would induce the influx of protons and chloride ions along
with water molecules (proton sponge ef fect), causing the vesicle
to swell and expand with the subsequent membrane rupture,
thus avoiding the endolysosomal entrapment.31
In this work, we have developed a redox-responsive
mesoporous silica nanocarrier that is able to slow down
premature drug release and showing enhanced tumor
accumulation, cancer cell targeting, and endosomal escape
capabilities (Scheme 1).
The nanocarriers were endowed with stimuli-responsiveness
using a redox-responsive self-immolative linker. The particles
were further modified with a versatile molecule containing
biotin and histidine to target cells and induce the
endolysosomal escape, respectively. The biological perform-
ance of these nanoparticles was extensively studied in vitro (2D
and 3D tumoral models) and using a tumor-bearing chicken
embryo model, demonstrating good performance regarding
tumor accumulation, cytotoxicity, and escape from the
endolysosomes.
To the best of our knowledge, this is the first time that the
active recognition of particles and their subsequent endosomal
escape have been demonstrated in 2D and 3D tumor models
using such a simple molecule, paving the way for future
nanomedicines that might improve the efficiency of cancer
treatments.
■ RESULTS AND DISCUSSION
Targeted Redox-Responsive Mesoporous Silica
Nanoparticles. The synthesis of MSNs was carried out
using a modified Stöber method, employing TEOS as silica
source and CTAB as structure directing agent, to obtain
colloidally stable and homogeneous spherical nanoparticles
presenting hexagonally ordered cylindrical mesopores (see
Supporting Information). Then, the particles were endowed
with stimuli-responsiveness behavior by grafting a redox-
responsive self-immolative molecule acting as linker and
gatekeeper. This linker would be cleaved thanks to the
difference in the concentration of glutathione in cancer cells
(2−10 mM in the cytoplasm vs 2−20 μM in the extracellular
fluids).32,33 A comprehensible representation of the synthesis
of the linker is depicted in Scheme 1B. As shown there, the
redox-responsive self-immolative linker 5 was synthesized from
compounds 2 and 3. Compound 2 was a protected analogue of
Scheme 1. (A) Schematic Representation of the Produced Material in This Work;a (B) Schematic Representation of the
Synthesis of the Redox-Responsive Self-Immolative Linker;b (C) Polyvalent Molecule Produced in This Work (HAVAB);c
(D) Schematic Representation of the Self-Immolative Degradation of the Linker;d
aMSNs were functionalized with a silylated redox-responsive linker and subsequently modified with SH-poly(ethylene glycol)-NH2 (PEG) to
finally graft a multifunctional molecule (denoted as HAVAB). The PEG chains were attached to the linker via thiol exchange, forming a disulfide
bond. HAVAB was coupled to the PEG using carbodiimide chemistry, leading to the formation of an amide bond. bReaction steps: (i) imidazole,
tert-butyldimethylsilyl chloride, dichloromethane, room temperature, overnight; 2,2′-Dipyridildisulfide, acetic acid, methanol, room temperature,
overnight; (iii) DBTL, toluene, reflux, 4 h; (iv) pTsOH, dichloromethane:methanol (1:1), reflux, overnight. For more details, please see Scheme
S2. cThe part in the right (green) is able to recognize cancer cells and can be tuned on-demand, increasing the versatility of the carrier. The part in
the left (yellow) is able to promote endosomal escape via proton sponge effect thanks to the histidine residues. dUpon application of a redox
stimulus, the disulfide bond is cleaved, producing an electron pair that attacks the carbamate through cyclization, triggering the 1,6-self-immolation.
ACS Applied Materials & Interfaces www.acsami.org Research Article
https://dx.doi.org/10.1021/acsami.0c21507
ACS Appl. Mater. Interfaces XXXX, XXX, XXX−XXX
B
a standard self-immolative monomer,34 which was synthesized
from commercially available 4-aminobenzyl alcohol. Com-
pound 3 was synthesized by reacting 2-mercaptoethanol with
2,2′-dipyridildisulfide to introduce the disulfide bond function-
ality responsive to redox species. Afterward, compounds 2 and
3 were reacted in the presence of a tin catalyst, and the benzyl
alcohol was finally deprotected under acidic conditions to
accomplish self-immolative compound 5.
The redox-responsive linker was then grafted to the particles
via silylation and subsequent condensation on the particles
surface to yield MSN-S. The grafting process was optimized in
terms of (1) the most adequate solvent for the silylation, (2)
the most convenient mixture of solvents for the grafting to the
nanoparticles, and (3) the best MSNs:Linker ratio. Overall, the
silylation was found to be most effective in DCM, as
demonstrated by the changes in the chemical environment of
the benzylic alcohol of 5 (reduction of signal 1 along with
appearance of signal 4) in the 1H NMR spectrum (Figure
S10). Then, a mixture of DCM/AcN was observed to provide
the best results for the grafting, as demonstrated by the higher
weight loss observed in the TG analysis (Figure S11). Finally,
the higher amount of additional organic matter observed by
TG analysis confirmed 1:7 as the best ratio for the
functionalization (Figure S13).
MSN-S were PEGylated (MSN-SP) via thiol exchange with
the redox-responsive linker. In this regard, increased colloidal
stability was observed as the different functionalization steps
were carried out (Figure 1A), as demonstrated by the
decreasing values of the polydispersity index (PDI) width.
The successful outcome of the different reaction steps was
confirmed by the weight loss observed (ca. 24% for MSN-S
and ca. 26.5% for MSN-SP) in the TG analysis (Figure S14) as
well as the changes in the FTIR spectrum, namely, the bands
from the carbamate group of 5 and the C−H groups of the
PEG chains) in the FTIR spectrum (Figure S15). The success
of each functionalization reaction was also confirmed by the
variations in the zeta potential, from −34.3 mV (MSNs) to
−30.5 mV (MSN-S) and −24.0 mV (MSN-SP). Besides, the
presence of organic matter was confirmed through TEM
microscopy upon treatment of MSN-SP with phosphotungstic
acid (Figure 1B). Additional physicochemical characterization
can be found in the Supporting Information.
The redox-responsiveness and subsequent self-immolation
of the linker were evaluated using a solution containing
dithiothreitol (DTT). A comprehensible representation of the
self-immolative process is depicted in Scheme 1D. Briefly, the
presence of redox species triggers the cleavage of the disulfide
bond of either MSN-S or MSN-SP, generating a free electron
pair. Such electron pair undergoes cyclization onto the
Figure 1. Representative characterization of the mesoporous silica nanoparticles developed in this work. (A) DLS measurements of MSNs, MSN-S,
MSN-SP, and MSN-SP-PEPT. The dispersibility of the material increased after each of the functionalization steps, as confirmed by the decreasing
values of the PDI width. This value is obtained from the width of the distribution at half its maximum height value. Hence, the lower the value, the
more monodispersed the sample and smaller the amount of aggregates in the sample. (B) TEM micrographs of MSNs vs MSN-SP. The samples
were stained with phosphotungstic acid, and the blurrier surface of MSN-SP indicated that the surface of the nanoparticles contained organic
matter. (C) Release experiment of MSN-SP. The experiment was carried out using Transwells, at 37 °C and under orbital stirring. DOX was
employed as cargo. One group was treated with DTT in PBS 1× as redox stimulus, while the other received only PBS 1×. The group treated with
10 mM DTT PBS 1× showed a 2-fold DOX release compared with the control group (PBS 1×) at 24 h and released additional ca. 40% after 48 h,
compared with the control group that did not receive any stimuli.
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carbamate, consequently initiating the 1,6-self-immolation of
the linker.18,35,36 Both MSN-S and MSN-SP were incubated
with the reducing agent, showing appreciable changes in their
C,N,S composition that were ascribed to the self-immolation
of the linker (see Supporting Information). Finally, MSN-SP
was loaded with doxorubicin (DOX) to evaluate the
responsiveness to redox stimuli. The experiment showed that
the redox-triggered material released a 2-fold amount of cargo
at 24 h and ca. 40% of additional drug release at 48 h,
compared with the control group (Figure 1C), confirming the
redox-responsiveness of the material and the feasibility of using
a self-immolative construct to hamper excessive drug release.
One of the key parts of this work was the design of a
multifunctional molecule that is able to mediate the active
recognition of the redox-responsive particles by cancer cells
and to promote their subsequent endosomal escape into the
cytoplasm (Scheme 1C). HAVAB was produced by employing
solid-phase peptide synthesis. Then, it was attached to the
particles using carbodiimide chemistry between the C-terminal
of the peptide and the amino groups of the PEG chain (see
Supporting Information), yielding MSN-SP-PEPT. These
nanoparticles exhibited the lowest PDI values and, con-
sequently, the highest colloidal stability (Figure 1A). The
rationale behind the increasing colloidal stability as the
different functionalization steps were carried out relies on
different factors. First, MSN-S was produced by attaching a
carbamate-containing self-immolative linker, showing a lower
PDI width than MSNs. This is in agreement with our previous
results, which showed that functionalizing the surface of
pristine MSNs or different hydrophobic mesoporous carbon
nanoparticles with a carbamate-based self-immolative polymer
resulted in increased colloidal stability.15,17 Then, MSN-S was
functionalized with PEG, displaying lower PDI width than
MSN-S. This would be a consequence of the hydration layer
generated around the PEGylated nanoparticles, which has been
shown to increase the colloidal stability of different
mesoporous silica nanoparticles.37,38 Finally, the attachment
of HAVAB, a readily water-soluble peptidic molecule,
produced MSN-SP-PEPT, which showed the lowest PDI
width, highlighting its colloidal stability and demonstrating its
suitability to be employed as drug delivery system via systemic
administration.
2D Biological Evaluation: Cellular Uptake. Because
biotin receptors are overexpressed in many tumoral cells, its
conjugation to different types of nanoparticles has yielded
nanomaterials with application in imaging, sensing, and drug
delivery.39 Indeed, its conjugation to MSNs has been
demonstrated to improve their internalization in biotin-
receptor-positive cells.37,40−42 In this sense, the presence of
the biotin targeting moiety promoted the preferential
accumulation of MSN-SP-PEPT in biotin-receptor-positive
cells rather than in healthy cells (see Supporting Information).
Then, the effect of HAVAB on the cellular uptake was further
evaluated by flow cytometry, using fluorescein-labeled nano-
particles and analyzing the fluorescence intensity inside the
cells. To that aim, MSN-SP-PEPT and MSN-S were placed
with HeLa cells. Besides, nanoparticles functionalized with
biotin but without the amino acids, denoted as MSN-SP-Biotin
(MSNs + linker + PEG + Biotin), was also included (Figure
2A). MSN-SP-PEPT displayed the performance, showing
greater internalization for all the concentrations studied in
two independent experiments (75 and 37.5 μg/mL; 18 and 9
μg/mL), highlighting the remarkable influence of HAVAB on
the cellular uptake. The noticeable difference between MSN-
SP-Biotin and MSN-SP-PEPT might rely on the effect of pH
on the histidine residues, as they progressively protonate as pH
acidifies.43 Then, the remarkable cellular uptake of MSN-SP-
PEPT might be explained as a consequence of two possible
phenomena, which might reinforce the active binding of biotin:
(1) the partial protonation would lead to local positive charge
effects, and the material would interact more tightly with the
cell membrane, which is negatively charged; or (2) it has been
demonstrated that peptides or proteins that present histidine
residues may lead to membrane fusion upon protonation,44−47
which is a phenomenon known to mediate the internalization
of some cell-penetrating peptides.48
2D Biological Evaluation: Endosomal Escape. Histi-
dine was used owing to the buffering capacity of the imidazole
ring at the acid pH of endosomes, which can lead to the escape
of the nanoparticles from the endosomes via proton sponge
effect.49−51 The endosomal escape capabilities were evaluated
loading the particles (MSNs or MSN-SP-PEPT) with calcein
(Figure 2B). The calcein method is a standardized approach to
evaluate the endosomal escape, owing to its membrane-
impermeable nature.52 Its fluorescence is self-quenched at high
concentrations, such as when it is trapped in the
endolysosomes, and it can be detected again when calcein
leaves the vesicles, as a consequence of their disruption.53−55
As shown in Figure 2B, MSNs loaded with calcein produced
low green fluorescence as a result of the nanoparticles being
trapped in the endolysosomes. However, cells incubated in the
Figure 2. 2D cellular models. Data are mean ± standard error of the
mean (SEM) (n = 3 in all cases). Statistical analysis was carried out
using two-tailed student’s t test (p < 0.05 was considered to be
significant). (A) Cellular uptake quantified by flow cytometry of
fluorescein-labeled MSN-SP-PEPT vs. MSN-S vs. MSN-SP-Biotin in
HeLa cells. The highest internalization degree was obtained for MSN-
SP-PEPT for all the experiments. # p < 0.05 vs MSN-SP-Biotin; § p <
0.05 vs MSN-SP-Biotin; * p < 0.05 vs MSN-S; ⧧ p < 0.01 vs MSN-S.
(B) Endosomal escape of free calcein (control), MSNs and MSN-SP-
PEPT. Green fluorescence was only detected for MSN-SP-PEPT,
confirming the endosomal escape. (C) Viability of A549 cells
employing drug-free and DOX-loaded MSN-SP-PEPT and MSNs
(50 μg/mL). MSN-SP-PEPT was shown to be biocompatible and
induced the highest inhibition of the cell viability when loaded with a
drug. ∥ p < 0.01 vs control; ϕ p < 0.01 vs MSNs and control; p < 0.01
vs MSN-SP-PEPT, MSNs (DOX) and control.
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presence of MSN-SP-PEPT loaded with calcein displayed
strong green fluorescence with a slight diffusion pattern. This
was associated with successful escape from the endosomes,56
likely through proton sponge effect,57 verifying the endosomal
escape features of this nanocarrier.
2D Biological Evaluation: Cytotoxicity. The particles
(MSN-SP-PEPT or MSN) were loaded with doxorubicin and
placed with A549 cells to evaluate their cytotoxicity on tumoral
cells. The amount of DOX loaded in the nanoparticles was
analyzed by thermogravimetric analysis and was found to be ca.
4%. As shown in Figure 2C, drug-containing MSN-SP-PEPT
significantly inhibited the cell viability (ca. 60% at 24 h and ca.
70% after 48 h). The much higher cytotoxic effect of this
carrier compared with the control group was ascribed to the
enhanced uptake of the particles bearing HAVAB. This effect
was observed to be independent of the tumoral cell line
employed because MSN-SP-PEPT could also inhibit the
viability of HeLa cells (see Supporting Information),
confirming the versatility of the produced nanocarrier in this
work.
3D Biological Evaluation: Endosomal Escape and
Penetration in Tumor Spheroids. The endosomal escape
features of the system were also analyzed using tumor
spheroids grown from A549 cells (Figure 3A). This in vitro
3D tumor model constitutes a powerful tool to evaluate the
biological performance of nanoparticles as it shows several
features of in vivo tumors.58 Calcein-loaded nanoparticles
(MSNs or MSN-SP-PEPT) were used. The results were
analogous to those in the 2D tumoral model. Although MSNs
remained trapped in the endolysosomes, as demonstrated by
the negligible green fluorescence detected, a strong fluo-
rescence was observed for MSN-SP-PEPT, clearly indicating
the achievement of the endosomal escape in the 3D tumor
model and confirming the versatility of the nanocarrier.
The distribution of particles in the spheroids was also
evaluated. As observed in Figure 3B, MSN-SP-PEPT
accumulated much more than bare MSNs in tumoral
spheroids, highlighting again the positive effect of HAVAB.
The depth reached by the nanoparticles, analyzed employing
ImageJ, demonstrated that MSN-SP-PEPT could penetrate
Figure 3. 3D cellular models. Red and green fluorescence indicate rhodamine B-labeled nanoparticles and calcein, respectively. (A) Endosomal
escape of free calcein, MSNs and MSN-SP-PEPT. A strong signal was detected for MSN-SP-PEPT, indicating the achievement of endosomal
escape. (B) Internalization of MSNs vs. MSN-SP-PEPT using confocal microscopy (top) and depth analysis of MSNs vs. MSN-SP-PEPT
employing the software ImageJ (bottom). The nanoparticles bearing HAVAB could reach deeper depth (250 μm vs 200 μm), demonstrating higher
penetration ability. (C) Imaging of spheroids incubated with drug-free and DOX-loaded MSN-SP-PEPT and MSNs (70 μg/mL). The latter group
showed the best spheroid inhibition. (D) Viability of A549 spheroids in terms of % volume employing DOX-loaded and drug-free MSN-SP-PEPT
and MSNs (70 μg/mL). § p < 0.05 vs Control; ⧧ p < 0.01 vs Control; * p < 0.01 vs MSN-SP-PEPT; p < 0.05 vs MSN-SP-PEPT; # p < 0.01 vs
MSNs (DOX); ∥ p < 0.05 vs MSNs (DOX); p < 0.05 vs MSNs.
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deeper in the spheroid (250 μm for MSN-SP-PEPT vs 200 μm
for MSNs). OVCAR8 spheroids were also incubated with such
nanoparticles, obtaining analogous results (see Supporting
Information). The rationale behind this higher penetration
might rely on the endosomal escape. On the one hand, it is
known that endolysosomal sequestration reduces the rate of
exocytosis of nanoparticles.59,60 Besides, Lu et al. demonstrated
that nanocarriers penetrate deeper in tumor spheroids via
transcytosis if the nanoparticles have undergone exocytosis
from the outer cells of the spheroid.61 In addition, Cui et al.
established the endolysosomal entrapment of nanoparticles as
a limiting factor for achieving transcytosis.62 In consequence,
MSN-SP-PEPT were preferentially internalized owing to the
overexpressed biotin receptors to then escape from the
endosomes. This would lead to the nanoparticles being
exocytosed toward inner areas of the A549 tumor spheroids,
to then undergo further cellular uptake through transcytosis,
thus improving the final tumor penetration.
3D Biological Evaluation: Cytotoxicity. The particles
(MSNs or MSN-SP-PEPT) were loaded with doxorubicin to
further evaluate their cytotoxic effect on A549 tumor
spheroids. The cytotoxicity was studied by analyzing the
spheroid volume at different time points. In this sense, the
spheroid images shown in Figure 3C were numerically
represented in Figure 3D to facilitate the understanding of
the trends observed in Figure 3C.63 The spheroids were
unaffected by unloaded MSN-SP-PEPT, confirming again the
high biocompatibility of the carrier and laying the foundations
for future analysis using animals. Moreover, MSN-SP-PEPT
loaded with DOX reduced the volume of the spheroids by ca.
30% after just 48 h and ca. 40% after a week, corroborating
their capability to penetrate in the tumoral spheroids and
deliver cytotoxic compounds to the cancerous cells.
Furthermore, drug-loaded MSN-SP-PEPT led to greater
cytotoxic effect than drug-loaded MSNs, in agreement with
all the previous results. Analogous results were obtained when
a lower particles concentration was employed (see Supporting
Information).
Tumor-Bearing Chicken Embryo Model. The chicken
embryo model allows the growth of human-like tumors,
providing valuable information about the biodistribution and
cytotoxic effect of nanoparticles.64,65 The tumors were grown
within 3−4 days by placing the tumoral cells in a Teflon ring
on the chorioallantoic membrane (CAM) of the chicken
embryo. Afterward, rhodamine B-labeled MSN-SP-PEPT were
injected into the A549 tumor-bearing chicken embryos
through a vein that was far from the tumor and allowed to
accumulate in the tumoral mass for 48 h (Figure 4). The red
fluorescence of the rhodamine B-labeled nanoparticles could
be observed in the tumoral mass 48 h after their
administration, confirming their ability to accumulate in the
tumor via EPR effect (Figure 4A). Indeed, many marketed
nanomedicines rely on this principle.66
The embryos were subsequently dissected and imaged
(Figure 4B). Overall, MSN-SP-PEPT accumulated preferen-
tially in the tumoral mass, and reduced accumulation was
noted only in the kidneys and the liver, indicating the low
clearance from the bloodstream. In addition, no significant
organ damage was observed. These observations further
confirmed the high colloidal stability of MSN-SP-PEPT,
given that it could circulate for up to 72 h in the embryos
without leading to aggregates, further emphasizing the
biocompatibility of this drug delivery system.
Finally, MSN-SP-PEPT was loaded with DOX and a
preliminary cytotoxicity study was performed. The drug-loaded
nanoparticles were injected into the bloodstream of the A549
tumor-bearing chicken embryos through an injection in a vein,
which were sacrificed after 72 h. As observed in Figure 4C, the
DOX-loaded nanocarrier could lessen the tumor weight by ca.
50% after only 72 h. In this sense, it was found that at least 25
μg of free DOX were needed to obtain comparable results
(data not shown), highlighting the suitability of MSN-SP-
PEPT to be employed as a nanomedicine in the treatment of
tumors.
Figure 4. (A) Biodistribution of MSN-SP-PEPT 48 h after the injection by fluorescence microscopy. Bright field (Left) and red fluorescence
(right). Labeled nanoparticles displayed red fluorescence in the tumor, verifying their passive accumulation via EPR effect. (B) Visualization of the
organs and tumor from the dissected chicken embryo. Bright field (left) and red fluorescence (right). MSN-SP-PEPT selectively targeted the
tumor, showing only minor accumulation in the kidneys and the liver. (C) Tumor growth inhibition by DOX-loaded MSN-SP-PEPT at a
concentration of 100 μg/mL. In this preliminary study, the nanocarrier showed its capability to lessen the weight of the tumor by ca. 50% after 72 h.
* p < 0.05 vs. Control. Data are mean ± SEM (n = 5). Statistical analysis was carried out using two-tailed student’s t test (p < 0.05 was considered
to be significant).
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■ CONCLUSIONS
In this research, redox-responsive mesoporous nanomaterials
showing remarkable targeting and endosomal escape features
was designed and produced. The particles were effective in
controlling premature drug release thanks to the redox-
responsive self-immolative molecule. A simple and versatile
molecule capable of targeting tumoral cells and to induce the
escape from the endosomes was here synthesized for the first
time and further grafted to the particles. The biological
capabilities of this nanocarrier was extensively studied using
2D and 3D tumoral models, demonstrating remarkable cellular
uptake and endosomal escape capabilities as well as excellent
cytotoxic profile. In addition, the presence of HAVAB
significantly enhanced the penetration of the particles in
tumor spheroids. Finally, the particles were shown to passively
accumulate in tumors of tumor-bearing chicken embryos. In
addition, the here produced particles were shown to
significantly reduce the weight of the tumor in a short space
of time, confirming the potentiality of the engineered
nanoparticle to addresses essential problems in current
nanomedicine.
■ MATERIALS AND METHODS
The majority of the reagents employed in this work were bought from
Sigma-Aldrich Inc.: ammonium nitrate; tetraethyl orthosilicate
(TEOS); fluorescein isothiocyanate isomer I (FITC); cetyltrimethy-
lammonium bromide (CTAB); 3-(aminopropyl)triethoxysilane
(APTES); rhodamine B isothiocyanate (RhB); phenyl chloroformate;
4-sminobenzyl alcohol; fibutyltin dilaurate (DBTL); N,N-diisopropy-
lethylamine (DIPEA); 2-mercaptoethanol; 2,2′-dipyridildisulfide;
imidazole; 3-(triethoxysilyl)propyl isocyanate; p-toluenesulfonic acid
(TsOH); tert-butyldimethylsilyl chloride (TBDMS-Cl); HS-PEG3500-
NH2 (PEG-SH); Tris(2,2′-bipyridyl)dichlororuthenium(II) hexahy-
drate (Ru); dithiothreitol (DTT); 2-chlorotrityl chloride resin; Fmoc-
5-Ava−OH (Ava); Fmoc-His(Trt)−OH (His); 1-hydroxybenzotria-
zole hydrate (HOBt); N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate (HBTU); dicyclohexylcarbodiimide
(DCC); biotin N-hydroxysuccinimide ester (NHS-Biotin); triisopro-
pylsilane (TIPS); trifluoroacetic acid (TFA); topotecan (TOP);
doxorubicin (DOX); N,N-dimethylformamide (DMF); tetrahydrofur-
an (THF); dimethyl sulfoxide (DMSO); acetonitrile (AcN);
dichloromethane (DCM). The rest of the chemicals (heptane, ethyl
acetate, ethanol, etc.) were of the highest quality and employed as
received.
Mesoporous Silica Nanoparticles. MSNs were produced
following a modification of the Stöber method.67 Briefly, 1 g (2.74
mmol) of CTAB, 480 mL of H2O and 3.5 mL of NaOH were mixed
in a flask and heated to 80 °C. Then, 5 mL, 22.4 mmol, of TEOS were
dropwisely added (0.25 mL/min) over 20 min, and then the reaction
was subsequently stirred at 80 °C for a further 2 h. Finally, the
nanoparticles were collected by centrifugation and washed with H2O
and ethanol. The organic template was removed by ionic exchange,
dispersing the nanoparticles in 500 mL of an ethanolic solution (95%)
of NH4NO3 (10 mg/mL) at 75 °C for 2 h, and subsequently
centrifuged and washed. The process was carried out three times. The
nanoparticles were finally stored in absolute ethanol.
The cellular experiments were carried out using labeled MSNs. For
that purpose, 1 mg (0.002 mmol) of FITC or 1.07 mg (0.002 mmol)
of RhB were reacted with 2.2 μL (0.009 mmol) of APTES in ethanol
(40 μL) for 2 h. Then, this mixture was added to 5 mL (22.39 mmol)
of TEOS, and the synthesis of MSNs was performed as above-
described.
The as-produced nanoparticles were characterized by fourier
transformed infrared (FTIR) spectroscopy, X-ray diffraction (XRD),
N2 adsorption analysis, thermogravimetric analysis (TGA analysis),
dynamic light scattering (DLS) and zeta potential, and transmission
electron microscopy (TEM).
Redox-Responsive Linker. Phenyl(4-(hydroxymethyl)phenyl)-
carbamate (1). Compound 1 was produced using a modified method
published previously.68 In brief, 6 g (48.7 mmol) of 4-aminobenzyl
alcohol was dissolved in 240 mL of THF/saturated aqueous sodium
bicarbonate/water (2:2:1). Then, 7 mL (55.8 mmol) of phenyl
chloroformate was dropwisely added, and the reaction mixture was
stirred at room temperature upon completion. Then, ethyl acetate was
employed to extract compound 1, and the organic phase was washed
several times with sodium bicarbonate, dried over sodium sulfate, and
finally removed in vacuo. Finally, chloroform was used to recrystallize
the crude, yielding compound 1. The product was characterized by 1H
NMR.
Phenyl(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-
carbamate (2). Compound 2 was synthesized using a published
method with minor modifications.68 In brief, 1 g (4.2 mmol) of
compound 1 and 0.31 g (4.52 mmol) of imidazole (0.31 g, 4.52
mmol) were dissolved in 20 mL of DCM. Then, 0.75 g (5 mmol) of
TBDMS-Cl were dropwisely added, and the reaction was stirred
overnight at room temperature. Then, the imidazole salts generated
were removed by filtration. Afterward, the solvent was removed in
vacuo, and the crude was purified on a silica column (DCM), leading
to compound 2. The product was characterized by 1H NMR.
2-(Pyridin-2-yldisulfaneyl)ethan-1-ol (3). Compound 3 was
produced following a published method.69 In brief, 2.42 g (10.98
mmol) of 2,2′-dipyridyldisulfide and 0.26 mL (4.55 mmol) of acetic
acid were dissolved in 40 mL of methanol. Then, 0.6 mL (8.52 mmol)
of 2-mercaptoethanol in 10 mL of methanol was added dropwise, and
the reaction was stirred for 48 h at room temperature. Afterward, the
crude obtained after removing the solvent was purified on a silica
column (heptane/ethyl acetate, 1:1) to yield compound 3. The
product was characterized by 1H NMR.
2-(Pyridin-2-yldisulfaneyl)ethyl (4-(((tert-butyldimethylsilyl)oxy)-
methyl)phenyl)carbamate (4). First, 1.9 g (5.3 mmol) of compound
2 and 1.1 g (5.9 mmol) of compound 3 were dissolved in 40 mL of
toluene. Then, 0.63 mL of DBTL were added, and the reaction was
heated at 110 °C for 4 h. Afterward, the solvent was evaporated to
yield a crude that was purified on a silica column (heptane/ethyl
acetate, 4:1), leading to compound 4. The product was characterized
by 1H NMR.
2-(Pyridin-2-yldisulfaneyl)ethyl (4-(hydroxymethyl)phenyl)-
carbamate (5). First, 2 g (4.44 mmol) of compound 4 was dissolved
in 50 mL of methanol and DCM (1:1). Then, 84.4 mg of TsOH in 15
mL of methanol and DCM (1:1) was added, and the reaction was
refluxed overnight. Afterward, the solvent was removed, and the crude
was purified on a silica column (heptane/ethyl acetate, 1:2) to lead to
compound 5. 1H NMR was employed to characterize the final
product.
MSNs Functionalized with the Redox-Responsive Linker
(MSN-S). Initially, 148.5 μL (0.6 mmol) of 3-(triethoxysilyl)propyl
isocyanate was dissolved in 0.5 mL of dry DCM (vial 1). Separately,
0.24 g (0.72 mmol) of compound 5 was dissolved in 1.2 mL of dry
DCM (vial 2). Afterward, vial 2 was dropwisely added dropwise over
vial 1, and the reaction was refluxed overnight. Once the silylation of
the redox-responsive molecule was accomplished, the mixture was
added to MSNs. For that purpose, 50 mg of MSNs was dispersed in 5
mL of AcN. Then, silylated compound 5 was incorporated three times
(additions spaced 2 h), and the reaction was refluxed overnight. Then,
the functionalized nanoparticles were collected by centrifugation and
washed first with AcN and then with methanol to yield MSN-S. The
nanoparticles were characterized in terms of FTIR spectroscopy,
TGA, zeta potential, and DLS.
PEGylation of MSNs Functionalized with the Redox-
Responsive Linker (MSN-SP). To PEGylate the as-produced
redox-responsive particles, 45 mg of MSN-S was dispersed in 15
mL of methanol. Then, 15 mg (0.004 mmol) of PEG-SH in 1 mL of
methanol was slowly incorporated into the mixture containing MSN-
S, and the reaction was stirred at room temperature overnight. Finally,
the nanoparticles were collected by centrifugation and washed with
methanol to yield MSN-SP, which was analyzed by FTIR spectros-
copy, TGA, DLS and zeta potential, and TEM.
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Biotinylated Histidine-Rich Peptide (HAVAB). The biotiny-
lated peptide (6, HAVAB, from Histidine-AminoValeric Acid-Biotin)
was produced through solid-phase peptide synthesis, using Fmoc-
protected amino acids (Figure S3). Amide bonds were formed by
adding 3.5 mL of DMF containing 300 mg (0.792 mg) of HBTU,
107.06 mg (0.792 mmol) of HOBt, and 0.275 mL (1.58 mmol) of
DIPEA to the resin (200 mg, 0.264 mmol). Then, the mixture was
shaken overnight. After that, the resin was extensively rinsed with
DMF to get rid of byproducts and unbounded amino acids. Then, 2
mL of piperidine (20% in DMF) was added to cleave the Fmoc-
protecting group. Afterward, the resin was thoroughly rinsed with
DMF, and the addition of the next amino acid was carried out as
mentioned above. After incorporating the last amino acid, 270 mg
(0.792 mmol) of NHS-Biotin and 0.275 mL (1.58 mmol) of DIPEA
were dissolved in 6.5 mL of DMF, and the mixture was added to the
resin and shaken in a 360° vertical rotator overnight.
Once all the components of compound 6 were incorporated, the
resin was thoroughly rinsed first with DMF and then with DCM.
Then, 1.2 mL of a cleavage mixture (TFA (95%), TIPS (2.5%) and
water (2.5%)) was added to the resin and kindly shaken for 2 h, to
release the peptide from the resin. Afterward, the solution was filtered
and collected. Then, a small amount of cleavage mixture was used to
rinse the resin, and both solutions were mixed. Such solution was
precipitated into cold ether and centrifuged. Then, the crude was
purified via molecular exclusion aschromatography, using Sephadex
G-25 as stationary phase and water as mobile phase. Compound 6 was
characterized by 1H NMR and mass spectrometry.
Targeted Mesoporous Silica Nanoparticles (MSN-SP-PEPT).
Thirty milligrams (0.04 mmol) of compound 6, 21.7 mg (0.11 mmol)
of DCC, and 12.1 mg (0.11 mmol) of NHS were dissolved in 1.2 mL
of dry DMF. The mixture was stirred for 1 h at room temperature for
acid activation. Afterward, 35 mg of MSN-SP were dispersed in 3.5
mL of dry DMF, and the solution that contained the acid-activated
peptide was added dropwise. The reaction was stirred at room
temperature for overnight. Afterward, the particles were centrifuged,
washed with DMF, ethanol, water and methanol, leading to MSN-SP-
PEPT. The as-synthesized nanoparticles were characterized in terms
of FTIR spectroscopy, TGA analysis, zeta potential, and DLS.
Release Experiments from MSN-SP. The response of the
particles to redox stimuli was studied using DOX-loaded MSN-SP.
For that purpose, MSN-SP were dispersed in a saturated solution of
DOX in methanol and stirred overnight. Then, the particles were
collected by centrifugation and washed until no drug could be
observed in the supernatant.
The release experiment was performed in vial using Transwells (3
per condition). PBS 1× solutions in the presence or absence of DTT
(10 mM) were used to replicate the cytoplasm of cancer cells. Briefly,
10 mg of particles were dispersed in 1.8 mL of the corresponding
solution to then transfer 0.5 mL of the corresponding dispersion into
each Transwell. The samples were kept with orbital stirring at 37 °C
during the whole experiment. The media were removed every time
point and studied using a fluorimeter (λexc = 480 nm, λem = 600 nm).
At every time point, old media was replaced by fresh media to keep
the volume constant.
2D Cellular Experiments. Two-Dimensional Cell Cultures. The
cellular experiments were carried out employing different cell lines
(MC3T3-E1, A549, OVCAR8 and HeLa). A549 or HeLa cells
(20,000 cells cm2) were plated at 37 °C in a humidified atmosphere of
CO2 (5%) in DMEM (1 mL) containing FBS (10%) and penicillin−
streptomycin (1%). OVCAR8 cells were plated analogously but in 1
mL of RPMI medium. MC3T3-E1 cells were plated similarly but
employing 1 mL of α-MEM. Afterward, different concentrations of
the corresponding nanoparticles were incubated with the cells for
different periods of time.
For the cytotoxicity studies, MSNs and MSN-SP-PEPT were
dispersed in a saturated solution of DOX (for experiments with A549
cells) or TOP (for experiments with HeLa cells, see Supporting
Information) in methanol, and the loading protocol was carried out as
described in the previous section. For the endosomal escape
experiments, MSNs and MSN-SP-PEPT were dispersed in a saturated
solution of calcein (CAL) in methanol, and the loading protocol was
carried out as described in the previous section.
Two-Dimensional Cell Viability. Cell viability was checked
through the Alamar Blue method. For that purpose, the Alamar
Blue solution (AbD Serotec) at 10% (v/v) was added to the cell
culture at the studied time points, according to manufacturer
protocols. After 4 h, aliquots of each well (200 μL) were placed in
96-well plates, and the absorbance intensity was recorded (λexc= 570
nm; λem= 600 nm) using a spectrophotometer (Unicam UV-500 UV−
visible).
2D Internalization Studies. Cells were seeded following the above-
described protocol for the fluorescence microscopy studies. Rhod-
amine B-labeled nanoparticles were employed.
MC3T3-E1 or HeLa cells were seeded in each well of a 6-well plate
for the flow cytometry studies. After 24 h, different concentrations of
fluorescein-labeled nanoparticles were added to the cells. After 2 h,
cells were washed with PBS and incubated with trypsin−EDTA at 37
°C for cell detachment. After 5 min, culture medium was added, and
the cells were collected by centrifugation (10 min, 1500 rpm). The
cells were resuspended in fresh medium and the fluorescence from the
surface of the cells was quenched using trypan blue (0.4%) to avoid
the detection of fluorescence from noninternalized particles. Flow
cytometry was carried out at an excitation wavelength of 488 nm and
measured at 530 nm. The trigger was set for the green fluorescence
channel. The data acquisition and analysis conditions were established
using positive and negative controls with the CellQuest Program of
Becton−Dickinson. The conditions were kept constant during all the
experiments. Three replicas per condition were employed. At least
10 000 cells of each sample were analyzed for statistical significance.
OVCAR8 or A549 cells were placed with different concentrations
of rhodamine B-labeled nanoparticles (MSNs or MSN-SP-PEPT) for
confocal laser scanning microscopy. After 2 h, noninternalized
nanoparticles were removed by rinsing each well with iced PBS.
The cells were fixed with cold ethanol (75%). Then, ethanol was
removed, and PBS was employed to rinse the wells. The cell nuclei
were stained using DAPI, and then the wells were washed with iced
PBS. The internalization was determined by confocal laser scanning
microscopy (λexc= 488 nm; λem = 610 nm).
3D Cellular Experiments. Three-Dimensional Cell Cultures.
Spheroids were grown in a 96 U-shaped-well plate. To that aim,
OVCAR8 or A549 cells (10 000 cells) were added to a well containing
200 μL of either DMEM or RPMI medium, respectively. Cellular
spheroids were grown for a week in a humidified CO2 atmosphere at
37 °C.
Spheroid Viability. The effect of the particles on the cellular
viability was assessed using A549 spheroids. Different concentrations
of DOX-loaded and drug-free nanoparticles were incubated with the
spheroids for 24 h. After that, noninternalized nanoparticles were
removed by rinsing the wells with PBS, and 200 μL of the appropriate
culture medium were added. The spheroids were then maintained for
a week in a humidified atmosphere at 37 °C and imaged at different
time points. The viability of the spheroids was studied through the
variation in the spheroid volume, using the formula:63,70
ϕ ϕ= * *V 0.5 (short ) long2
where “V” indicates the volume of the spheroid and “short ϕ” and
“long ϕ” indicate the short and long diameters of the spheroid,
respectively. The values for each diameter were determined analyzing
each image with the software ImageJ.
Internalization Studies in Spheroids. The studies of internal-
ization were performed employing OVCAR8 or A549 tumor
spheroids. For that purpose, rhodamine B-labeled nanoparticles
(MSNs or MSN-SP-PEPT) were incubated with the cellular spheroids
for 24 h. Then, the wells were washed with PBS 1× to removed non
internalized nanoparticles and the samples were transferred to an
Eppendorf tube. A paraformaldehyde solution (4%) at 4 °C was
employed to fix the spheroids overnight. After that, the spheroids
were rinsed with iced PBS 1× and treated with cold methanol for 0.5
h. Finally, the samples were kept in PBS 1× in the fridge for confocal
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microscopy. The confocal microscope generated multiple two-
dimensional images along the z-axis, from the top to the bottom,
that were then stacked using the software ImageJ to accomplish the
2D projection of the 3D spheroids.
Chicken Embryo Experiments. Tumor Formation. Freshly
fertilized chicken eggs were kept for 10 days in a humidified
atmosphere (60%) at 37 °C. On day 10, a small portion of the
eggshell was cut out, and a Teflon ring was then placed onto the CAM
membrane. After that, 100 000 A549 cells were carefully left in the
ring, and the window was closed to grow the tumor for 3 days.
Biodistribution Studies. Once the tumoral mass was completely
developed, a small window was opened in a different place, and
rhodamine B-labeled MSN-SP-PEPT were administered, using a
syringe, in a vein which was far from the tumor. Then, the window
was closed again and the embryos were kept in the incubator 2 more
days. Afterward, the eggs were visualized using a fluorescence
stereomicroscope and finally dissected to assess the distribution of
the particles in the tumor and the different organs.
Tumor Reduction. DOX-loaded rhodamine B-labeled MSN-SP-
PEPT were administered following the protocol described above at a
concentration of 100 μg/mL. The embryos (n = 5) were incubated
for 72 h and subsequently dissected to measure the weight of the
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